PROCRITline.com

Portal Home

For reimbursement information regarding other Centocor Ortho Biotech Inc. products, please click here.

PROCRITline.com Reimbursement Excellence

Please see full Prescribing Information, including Boxed WARNINGS, for PROCRIT^® (Epoetin alfa)

PROCRITline.com Survey

Thank you for visiting PROCRITline.com. In order to better meet your needs, we'd like to understand more about who you are and what you'd like to see on our website. The following survey will take but a few minutes to complete. No personal information is being collected as a result of this survey and all answers remain confidential. Thank you for your help in completing our survey.

1. Which of the following best describes you?

2. How experienced are you with reimbursement topics?

3. How did you find PROCRITline.com?

4. How do you access PROCRITline.com?

5. How often do you visit PROCRITline.com?

6. Why have you visited PROCRITline.com? (select all that apply). For each one that you select, please rate its overall value to you on a scale of 1 (not at all useful) to 5 (very useful).

Feature	Value to You
To obtain CMS (previously HCFA) 1500 or 1450 Samples
To review the latest state Medicare guidelines for PROCRIT reimbursement
To learn more about reimbursement in general
To access the Toolkits and Coding books for Oncology and Nephrology
To obtain copies of the Patient Assistance Forms
To submit Patient Assistance Forms electronically via the Online Registration feature

7. Would you like more information on how to complete PROCRIT reimbursement forms here on PROCRITline.com?

8. If you answered yes to Question 7, then would you like (check all that apply)?

More basic information
A "getting started" guide
More FAQ's (frequently asked questions)
More advanced information

Important Safety Information for PROCRIT^® (Epoetin alfa)

WARNINGS: INCREASED MORTALITY, SERIOUS CARDIOVASCULAR EVENTS, THROMBOEMBOLIC EVENTS, STROKE and INCREASED RISK OF TUMOR PROGRESSION OR RECURRENCE

Chronic Renal Failure:

In clinical studies, patients experienced greater risks for death, serious cardiovascular events, and stroke when administered erythropoiesis-stimulating agents (ESAs) to target hemoglobin levels of 13 g/dL and above.

Individualize dosing to achieve and maintain hemoglobin levels within the range of 10 to 12 g/dL.

Cancer:

ESAs shortened overall survival and/or increased the risk of tumor progression or recurrence in some clinical studies in patients with breast, non-small cell lung, head and neck, lymphoid, and cervical cancers (see WARNINGS: Table 1).

To decrease these risks, as well as the risk of serious cardio- and thrombovascular events, use the lowest dose needed to avoid red blood cell transfusion.

Because of these risks, prescribers and hospitals must enroll in and comply with the ESA APPRISE Oncology Program to prescribe and/or dispense PROCRIT^® to patients with cancer. To enroll in the ESA APPRISE Oncology Program, visit www.esa-apprise.com or call 1-866-284-8089 for further assistance.

Use ESAs only for treatment of anemia due to concomitant myelosuppressive chemotherapy.

ESAs are not indicated for patients receiving myelosuppressive therapy when the anticipated outcome is cure.

Discontinue following the completion of a chemotherapy course.

Perisurgery: PROCRIT^® (Epoetin alfa) increased the rate of deep venous thromboses in patients not receiving prophylactic anticoagulation. Consider deep venous thrombosis prophylaxis.

(See WARNINGS: Increased Mortality, Serious Cardiovascular Events, Thromboembolic Events, and Stroke, WARNINGS: Increased Mortality and/or Increased Risk of Tumor Progression or Recurrence, INDICATIONS AND USAGE, and DOSAGE AND ADMINISTRATION.)

Please see full Prescribing Information, including Boxed WARNINGS for PROCRIT^® (Epoetin alfa)

Medication Guide for PROCRIT^®
Please read the Medication Guide for PROCRIT^® and discuss with your doctor.

Patient Instructions for Use
Instructions if you or your caregiver has been trained to give PROCRIT^® injections at home.